Clicky

Clearside Biomedical, Inc.(CLSD)

Description: Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.


Keywords: Medicine Biopharmaceutical Ophthalmology Eye Macular Degeneration Retina Wet Age Related Macular Degeneration Macular Edema Uveitis Drug Therapies Veins Macula Of Retina Retinal Vein Occlusion Adverum Biotechnologies Non Infectious Uveitis

Home Page: www.clearsidebio.com

CLSD Technical Analysis

900 North Point Parkway
Alpharetta, GA 30005
United States
Phone: 678 270 3631


Officers

Name Title
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D. Pres, CEO & Director
Mr. Charles A. Deignan Chief Financial Officer
Dr. Thomas A. Ciulla M.B.A., M.D. Chief Medical Officer & Chief Devel. Officer
Ms. Jenny R. Kobin Head of Investor Relations
Mr. Rick McElheny VP of Corp. Devel.
Ms. Susan L. Coultas Ph.D. Chief Clinical Officer
Mr. Leslie B. Zacks Sec.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 161
Price-to-Book MRQ: 3.927
Price-to-Sales TTM: 2.6392
IPO Date: 2016-06-02
Fiscal Year End: December
Full Time Employees: 34
Back to stocks